Date of Graduation


Document Type

Thesis (MS)

Program Affiliation

Biomedical Sciences

Degree Name

Masters of Science (MS)

Advisor/Committee Chair

Karen Lu, MD

Committee Member

Rosemarie Schmandt, Ph.D.

Committee Member

Kwong K. Wong, Ph.D.

Committee Member

Samuel Mok, Ph.D.

Committee Member

Banu Arun, M.D.


Obesity is a significant risk factor for endometrial cancer, the most common gynecologic malignancy in the United States, but much remains unclear about the relationship between obesity-related factors and the development of endometrial cancer. Omentin, a recently discovered adipokine, has been shown to be present in lower levels in patients who are obese and/or insulin resistant. A case-control study was conducted using the serum of 140 women with endometrial cancer and 75 women with endometrial hyperplasia who were matched 1:1 based on body mass index (BMI) and menopausal status to women with no history of endometrial cancer (controls). The concentration of omentin in the patients’ serum was experimentally determined by conducting tests in triplicate on an enzyme-linked immunoadsorbent assay (ELISA) specific to human omentin. The mean serum omentin levels of women with endometrial hyperplasia and endometrial cancer were statistically significantly lower than controls, regardless of BMI. The mechanism that induces this change remains unknown, but these results present exciting promise for omentin’s use as a biomarker and role in understanding the relationship between obesity-related factors and endometrial carcinoma.


Omentin, Endometrial Cancer, Endometrial Hyperplasia